Roquefort Therapeutics plc (LON:ROQ – Get Free Report) shares shot up 23.3% during trading on Thursday . The stock traded as high as GBX 6.02 ($0.08) and last traded at GBX 5.49 ($0.07). 1,033,761 shares were traded during mid-day trading, an increase of 254% from the average session volume of 292,196 shares. The stock had previously closed at GBX 4.45 ($0.06).
Roquefort Therapeutics Price Performance
The company has a market cap of £7.03 million, a PE ratio of -445.00 and a beta of -0.09. The company has a 50-day moving average of GBX 5.27 and a 200 day moving average of GBX 6.48.
About Roquefort Therapeutics
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.
Further Reading
- Five stocks we like better than Roquefort Therapeutics
- What is the S&P/TSX Index?
- TJX Companies Can Hit New Highs; Double-Digit Upside to Follow
- What is the Nikkei 225 index?
- A Hidden Gem Retailer With 20% Upside
- Airline Stocks – Top Airline Stocks to Buy Now
- Zoom Stock’s Earnings Volatility Picked Up a Lot of Buyers
Receive News & Ratings for Roquefort Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roquefort Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
